Sugi Predict

Sugi Predict / Compounds / SCHEMBL3945277

SCHEMBL3945277

SCHEMBL3945277

CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CO)CC1

nearest known ligand 0.76

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.51
▸ DRD2 P14416 2/20 0.50
▸ ACACB O00763 9/20 0.49
▸ ACACA Q13085 5/20 0.47
▸ TDP1 Q9NUW8 1/20 0.45
▸ EPHX1 P07099 1/20 0.44
▸ NR1H2 P55055 1/20 0.44
▸ CKS1B P61024 1/20 0.43
▸ SKP1 P63208 1/20 0.43
▸ SKP2 Q13309 1/20 0.43
▸ CTSS P25774 1/20 0.43
▸ CTSK P43235 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7816031 1.00 KMT2A (0.51) KMT2ADRD2ACACBACACATDP1
SCHEMBL1491414 1.00 KMT2A (0.51) KMT2ADRD2ACACBACACATDP1
SCHEMBL3942686 0.93 KMT2A (0.56) KMT2ADRD2ACACBACACATDP1
SCHEMBL4377073 0.93 KMT2A (0.56) KMT2ADRD2ACACBACACATDP1
SCHEMBL190838 0.93 KMT2A (0.56) KMT2ADRD2ACACBACACATDP1
SCHEMBL3816616 0.93 KMT2A (0.56) KMT2ADRD2ACACBACACATDP1
Formaldehyde SCHEMBL28082239 0.89 KMT2A (0.54) KMT2ADRD2ACACBACACATDP1
Bicarbonate SCHEMBL1580718 0.89 KMT2A (0.57) KMT2ADRD2ACACBACACAEPHX1
SCHEMBL7817062 0.88 ACACB (0.51) KMT2ADRD2ACACBACACATDP1
SCHEMBL7817058 0.88 ACACB (0.51) KMT2ADRD2ACACBACACATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 — — EP disclosed
US-12384790-B2 Pteridinone compounds and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-08-12 — — US disclosed
WO-2024233846-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN LARKSPUR BIOSCIENCES, INC. (US) 2024-11-14 — — WO disclosed
US-11981658-B2 Substituted aminopyridine compounds as EGFR inhibitors YUHAN CORPORATION (KR) 2024-05-14 — — US disclosed
CN-117980297-A Substituted aminopyridine compounds as EGFR inhibitors 柳韩洋行 2024-05-03 — — CN disclosed
WO-2023201282-A1 NOVEL GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-10-19 — — WO disclosed
US-20230312587-A1 PTERIDINONE COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-10-05 — — US disclosed
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE HALIA THERAPEUTICS INC (US) 2023-06-15 — — US disclosed
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE HALIA THERAPEUTICS INC (US) 2023-06-15 — — US disclosed
US-20230086884-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS YUHAN CORPORATION (KR) 2023-03-23 — — US disclosed
US-5968819-A FOR MODIFYING FEEDING BEHAVIOR IN CONNECTION WITH EATING DISORDERS; FOR SCREENING ANTAGONISTS, AGONISTS; FOR PROBES TO DETECT RECEPTORS; ANTISENSE AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1999-10-19 — — US disclosed
EP-0915888-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS Takeda Chemical Industries, Ltd. (JP) 1999-05-19 — — EP disclosed
US-5843973-A Thiazolidinone compounds and composition for angina pectoris comprising the compounds as an active ingredient SANKYO COMPANY, LIMITED (JP) 1998-12-01 — — US disclosed
EP-0826686-A2 Tricyclic compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-03-04 — — EP disclosed
WO-1997046250-A1 METHODS OF MODIFYING FEEDING BEHAVIOR, COMPOUNDS USEFUL IN SUCH METHODS, AND DNA ENCODING A HYPOTHALAMIC ATYPICAL NEUROPEPTIDE Y/PEPTIDE YY RECEPTOR (Y5) SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-12-11 — — WO disclosed
WO-1997040051-A1 FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-10-30 — — WO disclosed
EP-0798298-A1 THIAZOLIDINONE COMPOUNDS OR ANGINA PECTORIS REMEDY OR PREVENTIVE CONTAINING THE SAME AS ACTIVE INGREDIENT SANKYO COMPANY LIMITED (JP) 1997-10-01 — — EP disclosed
EP-0782571-A1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION ARRIS PHARMACEUTICAL CORPORATION (US) 1997-07-09 — — EP disclosed
WO-1997020823-A2 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 1997-06-12 — — WO disclosed
WO-1996009297-A1 COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION ARRIS PHARMACEUTICAL CORPORATION (US) 1996-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE LRRK2, SNCA, PRKAR2B KMT2A 629/4885DRD2 1561/4885ACACB 3564/4885
US-11981658-B2 Substituted aminopyridine compounds as EGFR inhibitors EGFR, ERBB2, ERBB4 KMT2A 2693/4885DRD2 2618/4885ACACB 2540/4885
US-20230312587-A1 PTERIDINONE COMPOUNDS AND USES THEREOF DPYD, PKD1, TYMP KMT2A 909/4885DRD2 4264/4885ACACB 3209/4885
US-12384790-B2 Pteridinone compounds and uses thereof DPYD, PKD1, TYMP KMT2A 909/4885DRD2 4264/4885ACACB 3209/4885
US-20230086884-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 KMT2A 2693/4885DRD2 2618/4885ACACB 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.